-
Article
Open AccessEconomic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity
Poor literature report actual and detailed costs of chimeric antigen receptor (CAR) T-cell pathway in a real-life setting. We retrospectively collect data for all patients with relapsed/refractory aggressive l...
-
Article
Open AccessAxicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study
Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluat...
-
Article
Open AccessCorrection to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
-
Article
Open AccessMulticenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
The emergence of chimeric antigen receptor (CAR) T-cell therapy fundamentally changed the management of individuals with relapsed and refractory large B-cell lymphoma (LBCL). However, real-world data have show...
-
Article
Open AccessPrimary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure medication (ASM) prevention strategy has not been thoroughly investigated.
-
Article
Open AccessCost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Chimeric antigen receptor T cells (CAR-T) represent an innovation but raise issues for healthcare payers because of the uncertainty on impact at market launch, high cost and important organisational impact. Th...
-
Article
Open AccessFrequent ZNF217 mutations lead to transcriptional deregulation of interferon signal transduction via altered chromatin accessibility in B cell lymphoma
Recent exome-wide studies discovered frequent somatic mutations in the epigenetic modifier ZNF217 in primary mediastinal B cell lymphoma (PMBCL) and related disorders. As functional consequences of ZNF217 alterat...
-
Article
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study
To investigate neurotoxicity clinical and instrumental features, incidence, risk factors, and early and long-term prognosis in lymphoma patients who received CAR T-cell therapy.
-
Article
Open AccessBEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
One of the most critical issues in the management of Hodgkin lymphoma (HL) patients who resulted as primary relapsed or refractory is to obtain a minimal disease status before autologous stem cell transplantat...
-
Article
Correction to: Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
-
Article
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review
-
Article
Open AccessLong-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment with cladribine (2CDA), although relapse may occur during follow-up. The aim of the study is to revie...
-
Article
Open AccessImmune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) show efficacy in the treatment of non-Hodgkin lymphomas (NHL). However, these agents are associated with a unique group of side effects called immune-related adverse events ...
-
Article
2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS
-
Article
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity
Chimeric antigen receptor (CAR) T-cell therapy is an emerging highly effective treatment for refractory haematological malignancies. Unfortunately, its therapeutic benefit may be hampered by treatment-related ...
-
Article
Open AccessDual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma
Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 level...
-
Article
Open AccessTreatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients
Primary mediastinal B cell lymphoma is a rare entity and often should be promptly treated as a hematological emergency: The initial treatment decision is crucial for the management of this disease. An observat...
-
Article
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas
-
Article
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transpla...
-
Article
Open AccessThe treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients
The purpose of this study is to investigate the most suitable first-line approach and the best combination treatment for primary mediastinal large B-cell lymphoma (PMLBCL) as they have been matter of debate fo...
